LDC Members’ Entitlement to and Need for a Further Extension of Their Pharmaceutical Transition Period
LDCs Members have submitted a duly motivated request for an unconditional extension of the 2002-2016 pharmaceutical transition period (covering patents and data) and for relief from the requirements of TRIPS Article 70.8 and 70.9 (mailbox and marketing exclusivity provisions). This…